 | | Vol. 22.23 – 28 June, 2021 |
| |
|
|
| To identify predictors of clinical benefit to immune checkpoint blockade, investigators performed immunogenomic profiling of tumor samples from patients with relapsed small cell lung cancer.
[Nature Communications] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Using a transplantable mouse model of prostate carcinoma, scientists reported that tumor challenge leads to expansion of naïve neoantigen-specific CD8+ T cells and formation of a small population of non-recirculating tissue-resident memory T cells in several non-lymphoid tissues.
[Nature Communications] |
|
|
|
| Investigators described a novel approach in which human chimeric antigen receptor (CAR) T cells could be generated within the host upon injecting an adeno-associated virus (AAV) vector carrying the CAR gene, which they called AAV delivering CAR gene therapy.
[Blood Cancer Journal] |
|
|
|
| The authors performed comprehensive multi-omics analyses to characterize the landscape of crosstalk between epithelial-to-mesenchymal transition and immune evasion and their clinical relevance across 17 types of solid cancer.
[npj Precision Oncology] |
|
|
|
| Overall, 27% patients had high-risk cytogenetics and 15% had ISS stage III disease. Stem cell collection was performed after relapse in 72% and 35% of patients received maintenance therapy.
[Bone Marrow Transplantation] |
|
|
|
| Mice were followed for xenogeneic graft-versus-host disease score and survival. Human T-cell engraftment and as well as human T-cell subtypes were monitored in blood on days 14, 21, and 28 after transplantation.
[Bone Marrow Transplantation] |
|
|
|
| Injection of envelope-expressing antigen presenting cells one week post-CAR T-cell infusion also failed to stimulate CAR T-cell expansion in vivo.
[Molecular Therapy-Methods & Clinical Development] |
|
|
|
| Researchers investigated the effects of reducing the dose of posttransplantation cyclophosphamide (PTCy) followed by α-galactosylceramide, a ligand of iNKT cells, on the reciprocal balance between graft-versus-host disease (GVHD) and the graft-versus-leukemia (GVL) effect.
[Scientific Reports] |
|
|
|
| Investigators demonstrated efficient T cell transduction with the melanoma-reactive TIL1383I TCR through culturing with interleukin 7 in the absence of CD3 activation.
[Scientific Reports] |
|
|
|
|
| With the development of the anti-CD22 antibody-drug conjugate inotuzumab ozogamicin, the CD3-CD19 bispecific T-cell engager antibody blinatumomab, CD19 chimeric antigen receptor T-cell therapy, and the potent BCR-ABL1 tyrosine kinase inhibitor ponatinib, the outlook of acute lymphoblastic leukemia in both younger and older adults has substantially improved.
[Leukemia] |
|
|
|
| Several regenerative approaches involving the delivery of reparative cells or products have achieved kidney repair in experimental models of renal artery stenosis (RAS) and the delivery of mesenchymal stem/stromal cells has already been translated to human subjects with RAS with promising results.
[Trends in Molecular Medicine] |
|
|
|
| Scientists made a comprehensive review on the outcomes resulted from the combination of CAR T-cell immunotherapy and oncolytic virotherapy for the treatment of solid cancers.
[Cancer Gene Therapy] |
|
|
|
|
| Tessa Therapeutics Ltd. announced a collaboration agreement with the Agency for Science Technology and Research’s (A*STAR) Institute of Molecular and Cell Biology (IMCB) in Singapore to form a research laboratory. The collaboration is focused on IMCB’s research expertise, including new humanized patient-derived-xenograft and patient-derived-organoid models.
[Tessa Therapeutics Ltd.] |
|
|
|
| Takara Bio, Inc. announced that it has entered into a License and Supply Agreement with BioNTech Cell & Gene Therapies GmbH under which Takara Bio grants BioNTech a commercial license to use applicable patents relating to RetroNectin®.
[Takara Bio, Inc.] |
|
|
|
| In a move that will bring hope to liver transplant patients around the world, Lion TCR, a Singapore biotechnology company, has signed an exclusive worldwide licensing agreement with Duke-NUS Medical School to develop an innovative method of using gene-edited T cells to treat recurring cancers in the donated organ.
[Duke-NUS] |
|
|
|
| Cedars-Sinai has been awarded $11.99 million by California’s stem cell agency to launch a clinical trial testing a potential gene and stem cell therapy for amyotrophic lateral sclerosis (ALS).
[Cedars-Sinai] |
|
|
|
|
| September 1 – 4, 2021
Virtual |
|
|
|
|
|
| | FibroBiologics – Houston, Texas, United States |
|
|
|
| | University of Basel – Basel, Switzerland |
|
|
|
| | Institute of Oncology Research – Bellinzona, Switzerland |
|
|
|
| | Shanghai Immune Therapy Institute – Shanghai, China |
|
|
|
| | Sana Biotechnology – Multiple Locations, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
